1. Home
  2. SKE vs LQDA Comparison

SKE vs LQDA Comparison

Compare SKE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$32.87

Market Cap

3.1B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$38.14

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKE
LQDA
Founded
1979
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SKE
LQDA
Price
$32.87
$38.14
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$38.60
AVG Volume (30 Days)
1.3M
1.7M
Earning Date
03-30-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$69,216,000.00
Revenue This Year
N/A
$993.31
Revenue Next Year
N/A
$219.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
343.41
52 Week Low
$8.53
$11.26
52 Week High
$35.69
$46.67

Technical Indicators

Market Signals
Indicator
SKE
LQDA
Relative Strength Index (RSI) 58.42 44.38
Support Level $30.69 $38.88
Resistance Level $34.49 $40.95
Average True Range (ATR) 2.08 2.40
MACD -0.11 -0.86
Stochastic Oscillator 67.89 0.00

Price Performance

Historical Comparison
SKE
LQDA

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: